BACKGROUND: Prognostic factors in predicting outcomes in patients with head and neck squamous-cell carcinoma (HNSCC) are limited to the clinical-pathological parameters, including lymph node metastasis, location, grade and stage of the disease. AIM: To determine whether the expression of these proteins has a value in predicting patient outcome. METHODS: Ezrin, maspin and nm23-H1 immunohistochemistry in tissue samples of 120 patients with HNSCC were evaluated using the microarray technique. RESULTS: In determining the association among each of the three proteins and the clinical-pathological parameters, low maspin expression was the only one found to be significantly associated with high tumour grade (p = 0.007); all others showed no significant associations. In univariate analysis, patients with tumours expressing high ezrin had a shorter disease-free survival (DFS) of 51% than those with low ezrin expression (DFS 84%; p = 0.08). In multivariate analysis, tumours with the combination of loss of maspin and low histological grade had longer DFS (83%) compared with those with high maspin and high histological grade (DFS 42%; p = 0.08). CONCLUSION: Our study is the first to determine the value of ezrin and maspin in HNSCC in a large series of patients with long follow-up. Ezrin and maspin seem to have a potential prognostic value in patients with HNSCC but results should be confirmed with further studies.
BACKGROUND: Prognostic factors in predicting outcomes in patients with head and neck squamous-cell carcinoma (HNSCC) are limited to the clinical-pathological parameters, including lymph node metastasis, location, grade and stage of the disease. AIM: To determine whether the expression of these proteins has a value in predicting patient outcome. METHODS:Ezrin, maspin and nm23-H1 immunohistochemistry in tissue samples of 120 patients with HNSCC were evaluated using the microarray technique. RESULTS: In determining the association among each of the three proteins and the clinical-pathological parameters, low maspin expression was the only one found to be significantly associated with high tumour grade (p = 0.007); all others showed no significant associations. In univariate analysis, patients with tumours expressing high ezrin had a shorter disease-free survival (DFS) of 51% than those with low ezrin expression (DFS 84%; p = 0.08). In multivariate analysis, tumours with the combination of loss of maspin and low histological grade had longer DFS (83%) compared with those with high maspin and high histological grade (DFS 42%; p = 0.08). CONCLUSION: Our study is the first to determine the value of ezrin and maspin in HNSCC in a large series of patients with long follow-up. Ezrin and maspin seem to have a potential prognostic value in patients with HNSCC but results should be confirmed with further studies.
Authors: Thomas J Belbin; Bhuvanesh Singh; Richard V Smith; Nicholas D Socci; Volkert B Wreesmann; Marta Sanchez-Carbayo; Jessica Masterson; Snehal Patel; Carlos Cordon-Cardo; Michael B Prystowsky; Geoffrey Childs Journal: Arch Otolaryngol Head Neck Surg Date: 2005-01
Authors: K Pavelić; S Kapitanović; S Radosević; M Bura; S Seiwerth; L J Pavelić; J Unusić; R Spaventi Journal: J Mol Med (Berl) Date: 2000 Impact factor: 4.599
Authors: Nicolas F Schlecht; Margaret Brandwein-Gensler; Richard V Smith; Nicole Kawachi; Darcy Broughel; Juan Lin; Christian E Keller; Paul A Reynolds; Frank J Gunn-Moore; Thomas Harris; Geoffrey Childs; Thomas J Belbin; Michael B Prystowsky Journal: Head Neck Pathol Date: 2012-01-07
Authors: Herman Fernando; Tracey A Martin; Anthony Douglas-Jones; Howard G Kynaston; Robert E Mansel; Wen G Jiang Journal: Exp Ther Med Date: 2010-01-01 Impact factor: 2.447
Authors: Y F Costa; K C Tjioe; S Nonogaki; F A Soares; J R Pereira Lauris; D Tostes Oliveira Journal: Eur J Histochem Date: 2015-02-24 Impact factor: 3.188